Medtronic (MDT)

Business Overview

Medtronic is the slow grower in this medtech set, and its breadth is the reason. FY2025 net sales were $33,537M in the year to 25 April 2025; the April year-end needs a footnote in any peer table. Organic revenue growth was 4.9%, against 3.6% reported; the organic rate takes out currency and a small Other revenue line ($48M, against $221M a year earlier).

Its four segments, Cardiovascular, Neuroscience, Medical Surgical and Diabetes, span capital equipment, implants and consumables. In May 2025 it announced plans to separate the Diabetes business. The group files no consolidated recurring-revenue share and no installed-base count, only segment commentary. Without a filed recurring mix, the analysis rests on organic growth and cash conversion.

GAAP gross margin was 65.3% and GAAP operating margin 17.8%. Non-GAAP operating margin was 25.7% (+10 bps). Most of the gap is amortisation of acquired intangibles, $1,807M of the $2,693M added back; restructuring, litigation and acquisition items make up the rest. R&D was $2,732M, 8.1% of sales.

How the Numbers Read

Organic growth (4.9%). Medtronic's organic revenue excludes foreign exchange, Other revenue and significant M&A. At 4.9% it is the slowest in the FY2025 set, beside Abbott at 5.5%. Stryker grew 10.3% organic, Boston Scientific 15.8%, Edwards +10.7% at constant currency and Intuitive Surgical 21% in total, with no organic rate filed. The organic growth guide uses Boston Scientific's Urology segment as the acquisition trap. Medtronic's problem is the opposite: its reported rate sits below its organic rate, so the headline understates the business.

Free cash flow ($5.2B). Company-defined FCF was $5.185B: operating cash flow of $7.044B less capex of $1.859B. That was 73% of non-GAAP net earnings, the check on cash quality for a company whose earnings adjustments are large.

Recurring mix, not filed. Of these six, only Intuitive Surgical files a group recurring share (84%). Medtronic reports revenue by segment but no consolidated consumable or recurring figure, so it cannot be placed on the recurring-mix screen in the razor-and-blade guide.

Valuation Framework

Medtronic is the diversified end of the set, the peer against which the length of other companies' growth gets measured. Growth-adjusted P/E, forward P/E divided by organic growth, puts slow and fast growers on one axis. Bain puts the link between growth and multiples at about 2 turns of forward EV multiple per 100 bps of revenue growth (medtech above $3B revenue, valuations as of 14 January 2024). The growth-adjusted P/E guide shows why headline P/E alone misleads across growth rates as far apart as 4.9% and 21%.

What to Watch in the Financials

Organic against reported growth (4.9% vs 3.6%). The organic rate is the one that compares with peers. In FY2025 the gap was 1.3 points, from currency and the shrinking Other revenue line; read the footnote each quarter.

GAAP against non-GAAP operating margin (17.8% vs 25.7%). The gap is 790 bps. If the non-GAAP margin stalls while GAAP stays low, the adjustments are not turning into reported earnings.

FCF conversion (73%). Conversion of non-GAAP earnings falling below the low seventies would point to rising capex or working capital absorbing cash, in a business of a size that should produce it steadily.

With no group recurring figure, segment organic growth in Cardiovascular and Neuroscience is the best filed guide to where consumable revenue is accelerating and where capital-cycle exposure sits.

Key Risks

Growth duration. At 4.9% organic, margin expansion and capital returns carry more of the value than revenue growth does.

Portfolio complexity. Breadth dampens the risk from any one product but hides which franchises drive growth.

April fiscal year. A margin or growth table that sets Medtronic beside the calendar-year filers (all the others in this set) must footnote the 25 April 2025 year-end, or the comparison is eight months out of step.

What the Screening Shows

Against the Medtech Sector Primer screens:

• Organic growth: 4.9%, the slowest in the set.
• Gross margin: 65.3% GAAP, fourth of six (range 52.6% to 78.0%).
• Operating margin: 17.8% GAAP / 25.7% non-GAAP. Read both; peer tables default to GAAP.
• FCF: $5.2B company-defined; 73% conversion of non-GAAP earnings.
• Recurring mix: not filed at group level, so the recurring-mix screen cannot be applied.
• Scale: $33.5B of net sales, second in the set after Abbott's $44.3B.

Medtronic's 4.9% is the smallest growth divisor in the set, so a growth-adjusted ratio for it is the most sensitive to the growth input: one point of organic growth either way moves the ratio by roughly a fifth.